Biblio

Author Title [ Type

] Year

Filters: Author is Zimmermann, Martin [Clear All Filters]

Journal Article

Knörr F, Brugières L, Pillon M, Zimmermann M, Ruf S, Attarbaschi A, Mellgren K, G Burke AA, Uyttebroeck A, Wrobel G, et al. Stem Cell Transplantation and Vinblastine Monotherapy for Relapsed Pediatric Anaplastic Large Cell Lymphoma: Results of the International, Prospective ALCL-Relapse Trial. J Clin Oncol. 2020:JCO2000157.

Eckert C, Parker C, Moorman AV, Irving JAe, Kirschner-Schwabe R, Groeneveld-Krentz S, Révész T, Hoogerbrugge P, Hancock J, Sutton R, et al. Risk factors and outcomes in children with high-risk B-cell precursor and T-cell relapsed acute lymphoblastic leukaemia: combined analysis of ALLR3 and ALL-REZ BFM 2002 clinical trials. Eur J Cancer. 2021;151:175-189.

Woessmann W, Zimmermann M, Meinhardt A, Mueller S, Hauch H, Knörr F, Oschlies I, Klapper W, Niggli F, Kabickova E, et al. Progressive or Relapsed Burkitt Lymphoma or Leukemia in Children and Adolescents after BFM-type First-line Therapy. Blood. 2020.

Attarbaschi A, Möricke A, Harrison CJ, Mann G, Baruchel A, de Moerloose B, Conter V, Devidas M, Elitzur S, Escherich G, et al. Outcomes of Childhood Noninfant Acute Lymphoblastic Leukemia With 11q23/ Rearrangements in a Modern Therapy Era: A Retrospective International Study. J Clin Oncol. 2022:JCO2201297.

Alejo-Valle O, Weigert K, Bhayadia R, Ng M, Issa H, Beyer C, Emmrich S, Schuschel K, Ihling C, Sinz A, et al. The megakaryocytic transcription factor ARID3A suppresses leukemia pathogenesis. Blood. 2021.

Fischer U, Förster M, Rinaldi A, Risch T, Sungalee S, Warnatz H-J, Bornhauser B, Gombert M, Kratsch C, Stütz AM, et al. Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options. Nat Genet. 2015.

Conter V, Valsecchi MGrazia, Cario G, Zimmermann M, Attarbaschi A, Stary J, Niggli F, Pozza LDalla, Elitzur S, Silvestri D, et al. Four Additional Doses of PEG-L-Asparaginase During the Consolidation Phase in the AIEOP-BFM ALL 2009 Protocol Do Not Improve Outcome and Increase Toxicity in High-Risk ALL: Results of a Randomized Study. J Clin Oncol. 2023:JCO2301388.

Meissner B, Lang P, Bader P, Hoenig M, Müller I, Meisel R, Greil J, Sauer MG, Metzler M, Corbacioglu S, et al. Finding a balance in reduced toxicity hematopoietic stem cell transplantation for thalassemia: role of infused CD3+ cell count and immunosuppression. Bone Marrow Transplant. 2024.

Römer T, Vokuhl C, Staatz G, Mottaghy FM, Christiansen H, Eble MJ, Timmermann B, Klussmann JPeter, Elbracht M, Calaminus G, et al. Combination of nivolumab with standard induction chemotherapy in children and adults with EBV-positive nasopharyngeal carcinoma : Protocol of a prospective multicenter phase 2 trial. HNO. 2024.

Campbell M, Kiss C, Zimmermann M, Riccheri C, Kowalczyk J, Felice MS, Kuzmanovic M, Kovács G, Kosmidis H, Gonzalez A, et al. Childhood Acute Lymphoblastic Leukemia: Results of the Randomized Acute Lymphoblastic Leukemia Intercontinental-Berlin-Frankfurt-Münster 2009 Trial. J Clin Oncol. 2023:JCO2201760.

Buldini B, Varotto E, Maurer-Granofszky M, Gaipa G, Schumich A, Brüggemann M, Mejstrikova E, Cazzaniga G, Hrusak O, Szczepanowski M, et al. CD371+ pediatric B-cell acute lymphoblastic leukemia: propensity to lineage switch and slow early response to treatment. Blood. 2024.